Helsinn Healthcare SA
https://www.helsinn.com/public/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Helsinn Healthcare SA
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma
The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.
Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success
The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.
Company Information
- Industry
- Distributors
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Sapphire Therapeutics
- Helsinn Pharmaceuticals Beijing Co. Ltd.